Publications in collaboration with researchers from Hospital Vall d'Hebron (6)

2024

  1. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    The Lancet, Vol. 403, Núm. 10421, pp. 31-43

  2. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

    Gynecologic Oncology, Vol. 185, pp. 202-211

2023

  1. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 30, pp. 4768-4778

  2. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

    Journal of Clinical Oncology

2017

  1. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198